Bank Of New York Mellon Corp Erasca, Inc. Transaction History

Bank Of New York Mellon Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$2.74 - $4.44 $667,266 - $1.08 Million	243,528 New	243,528 $733 Million
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $824,345 - $1.82 Million	211,914 New	211,914 $913,000
Q3 2022 Nov 14, 2022	BUY	$5.82 - $10.68 $234,575 - $430,457	40,305 Added 21.43%	228,344 $1.78 Million
Q2 2022 Aug 15, 2022	SELL	$4.58 - $8.72 $90,015 - $171,382	-19,654 Reduced 9.46%	188,039 $1.05 Million
Q1 2022 May 11, 2022	BUY	$8.6 - $15.48 $903,610 - $1.63 Million	105,071 Added 102.39%	207,693 $1.79 Million

Q4 2021 Feb 11, 2022	BUY	$12.51 - $22.75 $654,885 - $1.19 Million	52,349 Added 104.13%	102,622 $1.6 Million
Q3 2021 Nov 12, 2021	BUY	$17.43 - $24.34 $876,258 - $1.22 Million	50,273 New	50,273 $1.07 Million

117

74.3M

7.1K

40.1K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $287M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.